| DIRECT COMPETITOR COMPARISON | |
| SUPG | BMY | CELG | SNY | Industry | | Market Cap: | 158.17M | 50.28B | 25.26B | 100.35B | 161.24M | | Employees: | 86 | 35,000 | 2,441 | 98,213 | 95 | | Qtrly Rev Growth (yoy): | 1.40% | 4.40% | 17.30% | 8.50% | 20.50% | | Revenue (ttm): | 41.22M | 21.14B | 2.56B | N/A | 46.74M | | Gross Margin (ttm): | 28.42% | 72.39% | 91.04% | 75.20% | 68.58% | | EBITDA (ttm): | 4.65M | 6.32B | 573.33M | N/A | -7.12M | | Oper Margins (ttm): | 7.83% | 26.65% | 16.83% | N/A | 2.25% | | Net Income (ttm): | -192.00K | 3.79B | 373.27M | N/A | N/A | | EPS (ttm): | -0.003 | 1.933 | 0.802 | N/A | -0.17 | | P/E (ttm): | N/A | 13.13 | 68.54 | N/A | 17.12 | | PEG (5 yr expected): | N/A | 2.51 | 1.12 | 2.59 | 1.04 | | P/S (ttm): | 3.95 | 2.40 | 10.02 | N/A | 4.17 |
|
| BMY = Bristol-Myers Squibb Co. | | CELG = Celgene Corporation | | SNY = Sanofi-Aventis | | Industry = Drug Manufacturers - Other | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.42 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | SNY | | Turning the world of drugs upside down
Sun 12:45pm -
at FT.com | | • | BMY | | 8 HealthCare Stocks With 3%+ Dividends
Sun 12:52am -
at Seeking Alpha | | • | BMY | | [$$] Jim Cramer's Best Blogs
Sat 8:54am -
at RealMoney by TheStreet.com | | • | BMY | | TradingMarkets 7 Stocks You Need to Know for Monday
Fri, Nov 27 -
TradingMarkets.com | | • | BMY | | A Mostly Meaningless FDA Approval
Fri, Nov 27 -
at Motley Fool | | • | BMY | | Biotech Bargains for Your Portfolio
Fri, Nov 27 -
at Motley Fool | | • | BMY | | 7 of the Most Efficient Companies on the Planet
Fri, Nov 27 -
at Motley Fool | | • | SNY | | European shares rise as banks regain poise
Fri, Nov 27 -
at FT.com | | • | SNY | | Sanofi Beats on Higher Revenue
Fri, Nov 27 -
Zacks.com | | • | SNY | | Sanofi-Aventis to participate in Russian project
Fri, Nov 27 -
at MarketWatch | | • | CELG | | Celgene Corporation to Present at the NASDAQ OMX 23rd Investor Program
Fri, Nov 27 -
Business Wire | | • | CELG | | Dream Stocks for Biotech Investors
Wed, Nov 25 -
at Motley Fool | | • | SNY | | Former chairman in Ratiopharm bid
Wed, Nov 25 -
at FT.com | | • | SNY | | A Schizophrenic Move by Merck?
Wed, Nov 25 -
at Motley Fool | | • | CELG | | Beware the Second Leg of the Next Great Recession
Mon, Nov 23 -
at Motley Fool | | • | CELG | | Yale Endowment Prefers ETFs, Selected Equities
Fri, Nov 20 -
Indie Research | | • | CELG | | Get Ready for a 25% Drop
Fri, Nov 20 -
at Motley Fool | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
